YAVNE, Israel, May 13, 2025 (GLOBE NEWSWIRE) -- MediWound Ltd. (Nasdaq: MDWD), a global leader in next-generation enzymatic therapeutics for tissue repair, today announced the publication of a peer-reviewed post hoc analysis in Wounds. The analysis is based on data from the Company’s Phase II ChronEx clinical trial in patients with venous leg ulcers (VLUs) evaluating the efficacy and safety of EscharEx® compared with collagenase ointment (SANTYL®), the only FDA-cleared enzymatic debridement agent commercial ...

Wound Healing Society (WHS) Symposium on Advanced Wound Care (SAWC) "These new data further validate EscharEx's unique mechanism of action and its potential to redefine the standard of care for chronic wound management," said Dr. Robert Snyder, Chief Medical Officer at MediWound. "We remain committed to advancing EscharEx through rigorous clinical development, with the goal of offering a meaningful, non-surgical solution for patients suffering from chronic wounds." Presentations at WHS and SAWC to highlight ...